Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Kiromic BioPharma Dividend Announcement
• Kiromic BioPharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Kiromic BioPharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.
Kiromic BioPharma Dividend History
Kiromic BioPharma Dividend Yield
Kiromic BioPharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Kiromic BioPharma stock? Use our calculator to estimate your expected dividend yield:
Kiromic BioPharma Financial Ratios
Kiromic BioPharma Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Kiromic BioPharma stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.